RNA-based Adjuvant

As a leader in the vaccine industry, Creative Biolabs has the ability to develop safe and effective vaccines of all kinds for various types of diseases. For peptide and protein subunit vaccines with weaker immunogenicity, selecting an adjuvant that is safe and can greatly enhance the efficacy of the vaccine is a very important issue in developing such vaccines. We have rich experience in adjuvant development and are proficient in the development of almost all types of adjuvants at present, and can help customers choose the most suitable adjuvants that best meet their needs.

Needs for A More Potent Adjuvant

Inadequate immunogenicity of subunit vaccines is an important reason limiting their clinical effectiveness. In order to solve this problem, scientists have conducted extensive and in-depth explorations in adjuvant development. Alum-based adjuvants is a mature and extensively applied adjuvant. Although it has been used clinically for more than ten years, however, its ability to provide only Th2-skewing immune response becomes inadequate for those intracellular pathogens that need to generate Th1-biased cellular responses to control.

Potential of RNA to be An Adjuvant

Toll-like receptors (TLR) mediate the recognition of a variety of danger signals that can act as adjuvants to enhance the effectiveness of the vaccine. In the TLR family, TLR3 and TLR7 / 8 recognize dsRNA and ssRNA respectively. Moreover, research has found that dsRNA or ssRNA modified by 5'-triphosphate can activate RIG-I–like helicases (RLHs) RIG-I and MDA5, and the activation signal can be transmitted through adapter molecules such as MyD88, TRIF, and Cardif, which can subsequently lead to the activation of various transcription factors that in turn cause the release of multiple proinﬂammatory cytokines and IFN-I. One example is the activation of the TLR3 and MDA5 signaling pathway by dsRNA analog polyinosinic-polycytidylic acid [poly (I:C)], which can significantly enhance the release of IFN-I and the generation of antiviral Th1 and CD8⁺ T cells responses. Although there are relatively few studies on ssRNAs as TLR7 / 8 agonists, there are also data showing that synthetic TLR7 / 8 agonists have a Th1-biased adjuvant effect, and an mRNA-based tumor vaccine has been found to have an intrinsic adjuvant effect. Therefore, rationally designing dsRNA and ssRNA molecules is a strategy to develop a new type of RNA-based adjuvant.

Services for RNA-based Adjuvant

RNA synthesis services
Various strategies for stabilizing RNA
Design and preparation of ssRNA and dsRNA adjuvants targeting different TLRs
In vitro and in vivo evaluations on the effect of prepared RNA adjuvant as well as RNA-adjuvanted vaccines
Custom design and synthesis of RNA-based adjuvant

Creative Biolabs' adjuvant development team has advanced technology and rich experience in the research and development of traditional aluminum adjuvants and various new adjuvants, which can help customers develop suitable vaccine adjuvants efficiently and at low cost. If you have a need for adjuvant development, please contact us!

All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.